ELDN NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Eledon Pharmaceuticals Inc · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 3.38 USD
-5.6% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is 7.2% above the Trend Line and sits at 62.5% of its 52-week range. The latest completed week returned -5.6%, after a -14.4% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 47/100 conviction, while the latest news-sentiment score is 54/100. Near-term considerations: volume confirmation is below normal; earnings are due in 11d.

Setup score 43 out of 100
Latest Close 3.38 USD 31 Jul 2026
1W Return -5.6% latest completed week
4W Return -14.4% short-term follow-through
12W Return -12.9% quarterly tape
Trend Breadth 32.7% 17 of 52 weeks active
Volume Ratio 0.9x vs 13-week average
What is working
  • The trend backdrop is active with a 16-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is constructive, supporting the smart-money activity read.
What could go wrong
  • Activity pressure is negative, which weakens the current setup.
  • The share remains more than 20% below its 52-week high.
  • The latest week was a sharp negative move.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -5.6% Latest completed week; four-week move -14.4%. Indicator stack 63/23 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Volatility 47/100 conviction; expected move 31.0%. News sentiment 54/100 63 relevant articles in the latest sentiment read. Event risk 11d Next report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 7.2% above the Trend Line and sits at 62.5% of its 52-week range. The latest completed week returned -5.6%, after a -14.4% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.9x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.7612-week average 0.85

12-week confirmation

Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure10/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.76Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -14.4% over four weeks, -12.9% over 12 weeks, and 0.0% over one year. The current trend has remained active for 16 consecutive weeks.

Performance by holding period

1W-5.6%
4W-14.4%
12W-12.9%
26W53.6%
52W0.0%
Active trend streak16 weeks
Active weeks in one year17
Trend breadth32.7%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.48Latest activity-pressure read.
Pressure change-234.6%Four-week change in activity pressure.
Leadership10.47Latest relative-leadership reading.
RS change-53.5%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 64% Model confidence 61%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength63/100Blend of value, momentum, and quality. Underlying universe rank 38; rank 1 is best.
Value56/100Relative valuation strength. Underlying universe rank 45; rank 1 is best.
Quality54/100Profitability and accounting quality. Underlying universe rank 47; rank 1 is best.
Momentum56/100Medium-term price momentum. Underlying universe rank 45; rank 1 is best.
Growth56/100Revenue and earnings growth. Underlying universe rank 45; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-25.4%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-59.6%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
1/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-19.4%
Net share repurchases relative to market value.
Shareholder yield
-19.4%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.1x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

ELDN shows volatility options pressure with a 47/100 conviction score, put-call volume ratio of 0.15, expected move of 31.0%, and Sharemaestro trend signal active.

Conviction47/100
Expected move31.0%
Put/call volume0.15
Pressure62
Speculation12
Volatility96
Trend agreement33
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment54/100

Weighted news tone is neutral across 63 relevant articles.

16 positive · 41 neutral · 6 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings11dNext report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
Options expected move31.0%Nearest-chain priced movement where available.
52-week drawdown-26.5%Distance below the 52-week high.
13-week volatility6.3%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher14 of 2612 weeks finished lower.
Best week+28.4%Week of 17 Apr.
Worst week-12.9%Week of 24 Apr.
Latest week-5.6%Week of 31 Jul.

Shape of recent returns

Strong gains12
Modest gains2
Flat weeks0
Modest losses7
Sharp losses5
Recent vol6.3%13-week weekly-return volatility.
Base vol12.5%52-week weekly-return volatility.
Up/down split28/23Count of positive and negative weeks in the 52-week window.
Average skew8.6% / -8.4%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape50/100

Trend, activity pressure, participation, and risk combine to a 50/100 tape read.

 Indicator analysis84/100

Latest 12-week confirmation: trend 12/12, activity pressure 10/12, relative leadership 12/12.

Activity pressure 0.76; No reversal markers Factors57/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 91; Small Cap Core rank 51 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options43/100

ELDN shows volatility options pressure with a 47/100 conviction score, put-call volume ratio of 0.15, expected move of 31.0%, and Sharemaestro trend signal active.

Volatility · Volatility expansion watch · Expected move 31.0% Sentiment54/100

Weighted news tone is neutral across 63 relevant articles.

Vanguard Capital Management (ELDN) discloses 5.05% passive stake in Eledon Pharmaceuticals Insiders50/100

No recent insider transaction evidence is stored.

 Earnings11d

Next report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20263.38 USD-5.6%3.15 USD2.74 USD-0.4810.475.9MOn
24 Jul 20263.58 USD-12.0%3.09 USD2.73 USD-0.2217.044.2MOn
17 Jul 20264.07 USD5.7%3.03 USD2.71 USD0.1430.274.7MOn
10 Jul 20263.85 USD-2.5%2.95 USD2.70 USD0.2817.718.4MOn
3 Jul 20263.95 USD4.5%2.87 USD2.68 USD0.3622.506.3MOn
26 Jun 20263.78 USD-3.6%2.79 USD2.66 USD0.4618.2316.5MOn
19 Jun 20263.92 USD9.8%2.72 USD2.65 USD0.6117.305.7MOn
12 Jun 20263.57 USD4.7%2.64 USD2.63 USD0.799.735.9MOn
5 Jun 20263.41 USD-10.5%2.58 USD2.62 USD1.037.004.3MOn
29 May 20263.81 USD-2.1%2.53 USD2.61 USD1.2313.693.9MOn
22 May 20263.89 USD2.4%2.55 USD2.60 USD1.2619.114.5MOn
15 May 20263.80 USD-2.1%2.54 USD2.58 USD1.3117.476.7MOn
8 May 20263.88 USD5.1%2.53 USD2.57 USD1.3819.486.1MOn
1 May 20263.69 USD6.5%2.49 USD2.57 USD1.3519.636.3MOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.